CA
NZ
UK
AU
IND
US
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced a significant change in its leadership, with Aziz Mottiwala departing as Chief Commercial Officer. This move is expected to have implications for the company's commercial strategy in the healthcare sector. The announcement comes as the company continues to …
Spero Therapeutics, Inc. (NASDAQ: SPRO) has signed a licensing arrangement with Innovent that grants rights to develop and eventually market a CD40L‑directed monoclonal antibody, designated SP001. The deal expands Spero’s portfolio of immunology assets and aligns with its strategy to bring novel biologics to …
IGC Pharma, Inc. (NYSE American: IGC) disclosed that it has refreshed its investor presentation, positioning the material for outreach to investors, analysts, and potential strategic collaborators. The update reflects the latest corporate and clinical information available as of the filing date.
MBX Biosciences (NASDAQ: MBX) has announced key leadership changes, appointing Steven Hoerter as CEO and John Smither as CFO. The moves reflect the company’s strategic direction as it continues to advance its pipeline in the biotechnology sector.
PLIANT THERAPEUTICS, INC. (NASDAQ: PLRX) has refreshed its board composition, adding two new directors to broaden its expertise and strengthen governance. The board now consists of nine members, reflecting a strategic decision to incorporate additional perspectives that support the company’s growth trajectory in the …
Revelation Biosciences unveiled a defensive strategy to ward off unsolicited takeover attempts. The biotech firm adopted a stockholder rights plan, commonly known as a poison pill, to deter investors from accumulating more than 10% of its outstanding common stock without board consent. The move …
Alto Neuroscience (NYSE: ANRO) completed a registered direct offering, selling 3,776,436 shares of common stock at $26.48 per share. The biotech firm secured approximately $93.9 million in net proceeds after underwriting discounts and expenses. The transaction closed on July 14, 2026, following regulatory clearance.
Apimeds Pharmaceuticals US has cleared a key hurdle in its effort to consolidate its share structure. The biopharmaceutical firm secured majority shareholder backing for a reverse stock split, a move aimed at adjusting its stock price and trading dynamics.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) announced a refreshed corporate presentation on July 13, 2026. The filing emphasizes a shift toward digital dissemination, positioning the firm’s website as the primary channel for upcoming investor materials.
Erasca (NASDAQ: ERAS) disclosed updated preliminary findings from its Phase 1 AURORAS-1 study evaluating ERAS-0015, a pan-RAS molecular glue designed to target RAS-mutant solid tumors. The results, announced on July 13, 2026, expand upon earlier data released in April 2026, incorporating additional patient data …
Please wait processing your request...